Diabetes drug's effect on breathing in obesity
Part of Hormones & metabolism clinical trials.
This study looks at how a type of diabetes drug (incretin-based) might affect breathing and muscle function in people with obesity. The goal is to see if the drug can improve how your lungs and respiratory muscles work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 25 and 60 years old.
- Your BMI is 30 or higher (obese).
- You do not have serious health conditions like uncontrolled heart disease, diabetes with complications, or chronic lung disease.
- You are not a smoker and haven't had recent surgery or injury to your legs.
- You are not currently on a structured weight-loss diet or taking weight-loss medications.
- You agree to take part voluntarily.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how insulin affects blood vessels and the brain in people with obesity and insulin resistance, compared to healthy-weight individuals. It may help explain why obesity raises heart and blood vessel risks.
This study examines how obesity affects your breathing capacity and muscle strength, especially when your lungs show a restrictive pattern (difficulty expanding fully). Researchers will assess your body composition, physical function, and respiratory muscle endurance to better understand these connections.
This study examines how excess weight affects how insulin works in small blood vessels and overall fitness in people with Type 1 Diabetes. Researchers want to understand if obesity makes diabetes management harder and whether this knowledge can help future treatments.
This study tests whether a GLP-1 receptor agonist (a type of diabetes medicine) changes how the brain responds to insulin in people with different body sizes. It may help understand if this drug can improve brain function related to insulin.
This study is testing whether a new class of medications, known as GLP-1/GIP receptor agonists, can help improve symptoms and heart health in people who have heart failure with preserved ejection fraction and are overweight or obese. It is a registry that tracks participants' health over time to learn about the treatment's effects.
This study looks at how different body shapes in people with obesity affect breathing and exercise ability. Researchers want to understand these connections better to potentially improve health outcomes.
Hear when a new Obesity (BMI>30) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.